Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00927394 · ClinicalTrials.gov registry record · Phase 4
Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus
A Phase 4 study of Hypertension, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,143
- Enrollment target
- 4
- Study locations
NCT00927394 is a Phase 4 study of Hypertension that has completed, run by Novartis. The registered enrollment target is 1,143 participants, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (67% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT00927394, a Phase 4 study of Hypertension, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,143 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of the study was to evaluate the blood pressure (BP)-lowering efficacy of the combination of aliskiren and valsartan, as initial therapy, compared to valsartan monotherapy in Type II Diabetic patients with Stage II hypertension.
Conditions Studied
Interventions
- DRUG Valsartan
- DRUG Aliskiren
- DRUG Placebo for Aliskiren
- DRUG Placebo for Valsartan
Study Locations (4)
Delaware
- Investigative Site - Newark
Missouri
- Investigative Site - Kansas City
New Jersey
- Investigative Site - Camden
Pennsylvania
- Investigative Site - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,143 participants |
| Start Date | 2009-05 |
| Est. Completion | 2011-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00927394
The ClinicalTrials.gov registry entry for NCT00927394 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,143 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (67% lower). The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 4 interventions - of which Valsartan is the first listed.
NCT00927394 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Delaware, Missouri, New Jersey.
Frequently Asked Questions
What is clinical trial NCT00927394 about?
NCT00927394 is a clinical study titled "Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus". The purpose of the study was to evaluate the blood pressure (BP)-lowering efficacy of the combination of aliskiren and valsartan, as initial therapy, compared to valsartan monotherapy in Type II Diabetic patients with Stage II hypertension.
What is the current status of trial NCT00927394?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,143 participants. The study started on 2009-05. Estimated completion is 2011-10.
What conditions does trial NCT00927394 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT00927394?
The interventions under investigation include: Valsartan (DRUG), Aliskiren (DRUG), Placebo for Aliskiren (DRUG), Placebo for Valsartan (DRUG).
Who is sponsoring clinical trial NCT00927394?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00927394 being conducted?
This trial has 4 study locations across Delaware, Missouri, New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment With Aspirin After Preeclampsia: TAP Trial
RECRUITING · Phase 4
-
Impact GLP-1 Agonists Following Bariatric
RECRUITING · Phase 4
-
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
RECRUITING · Phase 4
-
Bridging the Evidence-to-practice Gap
RECRUITING · Phase 4
-
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
RECRUITING · Phase 4
-
Secondhand Tobacco Smoke and Cardiovascular Disease
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.